Roivant Sciences appoints Meghan FitzGerald to board and Ilan Oren as Chairman

Roivant Sciences Ltd.

Meghan M. FitzGerald appointed as Class II director and member of Nominating & Governance Committee, effective March 13, 2023.
FitzGerald is a global healthcare strategist with experience at Cardinal Health, Pfizer, Sanofi, and adjunct professor at Columbia University.
Board appointed Ilan Oren as Chairman; Oren has been a director since 2014 and Co-CEO of Dexcel Pharma.
FitzGerald will receive cash and equity compensation per company's Non-Executive Director Compensation Policy; initial equity grant in April 2023.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Ilan Oren

Chairman of the Board

ROIV · Roivant Sciences Ltd.

Filed: March 16, 2023, 7:59 PM ET

In addition, the Board has appointed Ilan Oren as Chairman of the Board.

Appointed

Meghan M. FitzGerald

Class II Director

ROIV · Roivant Sciences Ltd.

Effective: 2023-03-13
Filed: March 16, 2023, 7:59 PM ET

On March 13, 2023, the Board of Directors (the “Board”) of Roivant Sciences Ltd. (the “Company”) appointed Meghan M. FitzGerald, DrPH, to serve as a Class II director of the Company and as a member of the Nominating and Governance Committee of the Board, effective as of that date, filling a vacancy on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ilan Oren was appointed as Chairman of the Board at Roivant Sciences Ltd..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

In addition, the Board has appointed Ilan Oren as Chairman of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Meghan M. FitzGerald was appointed as Class II Director at Roivant Sciences Ltd..

Action: appointed
Role: Class II Director

Exact text from the filing

On March 13, 2023, the Board of Directors (the “Board”) of Roivant Sciences Ltd. (the “Company”) appointed Meghan M. FitzGerald, DrPH, to serve as a Class II director of the Company and as a member of the Nominating and Governance Committee of the Board, effective as of that date, filling a vacancy on the Board.

View on SEC.gov

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-012083

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.